The long term effects of two dose regimens of latanoprost (PhXA41) administered to eyes concomitantly treated with timolol which had not adequately been controlied by timolol alone were compared. A total of 50 patients, 17 with primary open angle glaucoma and 33 with capsular glaucoma, were recruited from five clinics. All had glaucomatous visual field defects and an intraocular pressure (IOP) of at least 22 mm Hg despite treatment with 0*5% timolol twice daily. Patients were randomised to two treatment groups. In one group 0.006% latanoprost was given twice daily, in the other group placebo was given at 8 am and latanoprost at 8 pm for 3 months, with concomitant timolol treatment in both groups. Average daytime IOP (mean (SD)) at baseline (on timolol alone) and after 4 and 12 weeks' treatment was 24*8 (3.6), 16-8 (4.3), and 15*7 (2.4) mm Hg respectively with once daily application of latanoprost and 24-9 (2.9), 18*1 (3.0), and 18-0 (3.6) mm Hg respectively with latanoprost twice daily. No clinically significant side effects were observed during treatment. Latanoprost causes a marked and sustained IOP reduction in eyes which are also being treated with timolol. Latanoprost given once daily is at least as effective and probably superior to a twice daily dose regimen (BrJ Ophthalmol 1995; 79: 12-16) Several previous studies have demonstrated that the phenyl substituted prostaglandin F2a analogue, 13,14-dihydro-17-phenyl-18, 19, 20-trinor-prostaglandin F2a-isopropylester (latanoprost, PhXA41) and its epimeric mixture PhXA34 reduce significantly the intraocular pressure (IOP) in normal, ocular hypertensive, or glaucomatous eyes."18 The present study was undertaken to obtain more information on dose regimen, long term effect, and additivity to a 13 adrenergic antagonist, timolol.
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Latanoprost has a long duration of effect on IOP, but whether it should be administered once of twice daily is unclear. In two dose finding studies with the epimeric mixture PhXA34 a duration ofat least 24 hours was observed but the effect 24 hours after the dose was less pronounced than that seen at 12 hours after the dose.' 2 Such an attenuation of the effect was not observed in a study on hospitalised patients treated with latanoprost,7 and in one dose regimen study administration of 0-006% latanoprost once daily was at least as effective as twice daily.4
In a first dose finding study with twice daily administrations of latanoprost, ocular hypertensive eyes were treated for 4 weeks.5 There was no significant difference between the three concentrations of latanoprost eye drops used; 0 0035%, 0 006%, and 0-0115%, and all were significantly better than placebo. The initial response, on the second day of treatment, was good with a 31-38% reduction of the IOP, but after 1 week of treatment there was some diminution of effect and after 4 weeks the IOP reduction was between 19 and 22% for the three concentrations of latanoprost used. A partial diminution in the IOP effect was also observed by Camras et al after 5 days of treatment twice daily with 0-01% latanoprost, but not with 0003%. Fristrom and Nilsson also noted some reduction of the IOP effect with 0-006% latanoprost given twice daily for 1 week, similar to that observed for 2% pilocarpine administered three times daily.9 They also found that the effect on IOP of latanoprost and pilocarpine was at least partially additive.9 Both drugs act on outflow; latanoprost has no effect on aqueous flow.'68 Thus one would expect latanoprost and an aqueous flow suppressor to be a better combination. The effect on IOP of prostaglandin F20-isopropylester (PGF20-IE) has previously been found to be additive to that of timolol'"" and a direct comparison of the additivity of latanoprost to timolol 0 5% twice daily and pilocarpine 2% three times daily suggested that pretreatment with pilocarpine reduced the effect of latanoprost on IOP. 12 The present study was designed to evaluate the effect of latanoprost administered either once or twice daily in addition to timolol. Treatment was given for 3 months to be able to detect any long term diminution in the effect of the drug on IOP.
Patients and methods

SUBJECT SELECTION
The study was performed as a five centre, randomised, parallel, double masked study of latanoprost, 0-006%, given either once, in the evening, or twice daily for 12 
Results
Of the 50 patients who entered 48 were able to complete the study. The two patients who withdrew were in the group which administered latanoprost once daily. One patient developed a keratitis after 4 weeks' treatment and one withdrew after 6 weeks and 4 days' treatment owing to difficulties in distinguishing between the dropper bottles.
Oral 1 blocking agents were used by one patient in the twice daily group compared with seven patients in the once daily group. Otherwise there were no major differences between treatment groups with respect to demographic or clinical data ( Table 2) .
The mean diurnal IOPs at baseline and weeks 4 and 12 for the two groups are presented in Table 3 , and the IOPs measured at 4 pm at baseline and at 2 week intervals for 12 weeks are shown in Figure 1 . After 4 weeks' treatment the mean diurnal IOP was reduced by 8O0 mm Hg in during the study are presented in Figure 2 . A slight trend towards increased hyperaemia in latanoprost treated eyes was observed but the average hyperaemia after 4 and 12 weeks of treatment was between none and mild in both groups. Individual variations were seen but no patient discontinued the study because of unacceptable hyperaemia. At baseline four of 25 in each group had a conjunctival injection graded as at least a mild hyperaemia. After 4 and 12 weeks of treatment this increased to seven to eight patients per group, but there was no increase in the number ofpatients judged to have at least a moderate hyperaemia. Two such patients were seen in the once daily group at baseline but in this group all patients were judged to have less than moderate hyperaemia after 4 and 12 weeks' treatment. In the twice daily group there was one patient with moderate hyperaemia at baseline and two patients with moderate to severe hyperaemia after 4 and 12 weeks' treatment.
In the once daily group there was one report of a mild stiffness in the study eye at baseline and one report of moderate foreign body sensation in the study eye after 4 weeks' treatment. In the twice daily group mild ocular symptoms were recorded for one eye at baseline, two eyes after 2 and 4 weeks' treatment respectively, and in one eye after 8 weeks' treatment. Mild ocular symptoms in both eyes or the fellow eye only were reported by between one and four of the 50 patients on the various examination days.
No flare was seen in any patient on any examination apart from fluorescein flare after IOP measurements. On three occasions in three different patients one cell was observed in the anterior chamber, two patients at the baseline examination and one on once daily latanoprost for 10 weeks. Photographs of the anterior segment were taken for documentation ofiris colour because studies on cynomolgus monkeys have shown increased iris pigmentation with long term treatment (unpublished observation).
Masked observation of the photographs of the anterior segment revealed no changes in iris pigmentation throughout the study. There were no changes in visual acuity or refraction.
Discussion
This study was designed to compare two dose regimens oflatanoprost administered in addition to timolol. Latanoprost was given to patients with inadequate IOP control, and thus placebo was not used and timolol was not washed out before adding latanoprost. Most patients had been on timolol for at least 6 months and some were taking oral fi blockers. Consequently, the effect on IOP of timolol alone at the start of the study is not known. Comparison of the two dose regimens can be made but it is not possible to calculate the combined effect of the two drugs. The results, however, are clear; latanoprost causes a marked and significant reduction of IOP in patients who are using timolol, which has been previously shown for PGF2a-IE.' " The magnitude of the effect in the present study is better than in a previous study where 0'006% latanoprost was given twice daily for 1 month in otherwise untreated eyes. 5 The results support the assumption that because of their different mechanisms of action the effects of timolol and latanoprost are completely additive. 6 The present study also demonstrates that 0-006% latanoprost given once daily seems to be superior to twice daily administrations. Nagasubramanian et al made the same observation after 2 weeks of treatment with the same two dose regimens. 4 As the results of two independent studies are the same it is unlikely that this is due to chance variation. Alternative explanations for this unusual response should be considered such as a dual effect of latanoprost on aqueous humour dynamics or the development of a moderate degree of receptor tolerance.
Latanoprost was administered in the evening to the once daily group and IOP was determined [12] [13] [14] [15] [16] [17] [18] [19] [20] hours later, whereas IOP determinations were made 4-8 hours after the dose in the twice daily group. Thus one obvious possibility is that latanoprost affects aqueous humour dynamics in more than one way, a short duration effect -less than 12 hours -which would increase IOP and a long duration IOP reducing effect. In early studies with PGF20-IE an initial increase in IOP was observed, presumably due to intraocular vasodilatation.'3 An intraocular vasodilatation and an increased episcleral venous pressure lasting for 8 hours is, however, an unlikely explanation to the difference between the two dose regimens. Latanoprost, unlike PGF2,-IE, has only a slight effect on intraocular blood flow.'4 No dual effect on aqueous outflow has been observed for either PGF2a or latanoprost in monkeys; both increase uveoscleral flow without measurable effect on conventional outflow.' '7 A short duration increase of aqueous flow could explain the observed results, but previous studies both using PGF2,a-IE and latanoprost have failed to demonstrate any effect on aqueous flow in the human eye.6" 11 In those studies latanoprost was given alone and in the present study latanoprost was added to eyes with timolol suppressed aqueous flow, and the effect of latanoprost on aqueous flow in timolol treated eyes has not been determined. However, an increase of suppressed aqueous flow by latanoprost cannot explain the observation that the same difference between the two dose regimens was found in eyes not treated with timolol,4 and Ziai et al found that latanoprost had no effect on non-stimulated aqueous flow at night.8 Still, none of these studies were designed to detect a small change in aqueous flow and the possibility that latanoprost causes an increase of aqueous flow of, for example, 10% for 8 to 12 hours cannot be excluded.
The other possibility, is a development of a moderate degree of receptor tolerance. One argument in favour of this explanation is that the difference between the two dose regimens is not seen until after a few days of treatment. In fact, Nagasubramanian et al found that 0-006% latanoprost given twice daily was significantly superior to the same dose given once daily on the second day of the study but significantly inferior after 14 days of treatment.4 Thus, the observed phenomenon that latanoprost given once daily seems to be superior to the same dose given twice daily may be based on development of some degree of receptor tolerance. Continued treatment after the first 2 weeks does not result in further loss of effect.
In the present study a small but statistically significant reduction in IOP also occurred in the contralateral eye. A drug related effect in the fellow eye cannot be expected with latanoprost as the dose given is very small and latanoprost is rapidly metabolised with a half life in plasma of only about 10 minutes. 19 Some of the fellow eyes were being treated with timolol, but these eyes did not differ from untreated fellow eyes with respect to change in IOP during the study. Improved compliance during the study cannot explain the contralateral effect which was small and of no clinical significance. It perhaps is explained by a regression towards the mean since a lower limit for IOP was part of the inclusion criteria and the IOP of the two eyes tend to vary in concert. 20 Side effects were minimal in the present study. One patient interrupted the study owing to a keratitis that was judged as non-drug related. Flare was not observed in either group, and previous studies with various techniques have found no significant effect of latanoprost on the blood-aqueous barrier.8 A slight increase in conjunctival injection was noted, but was not clinically significant. There was no increase in ocular symptoms and no change in visual acuity, or refraction. Thus there is a large difference in side effects between the phenyl substituted analogue latanoprost and its mother compound PGF2a-IE, which caused marked conjunctival hyperaemia and ocular irritation in large doses. '3 In conclusion 0-006% latanoprost given once daily causes marked reduction of the IOP in patients being treated with timolol concomitantly, and administration once daily is not only adequate but probably superior to twice daily. Thus these results support the view that latanoprost may become a valuable addition to the treatment of glaucoma. 
